SCHEMBL4638149

SCHEMBL4638149

CCCCC(C)(C)C(=O)NC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 3/20 0.40
CCR1 P32246 1/20 0.40
CCR5 P51681 1/20 0.40
CXCR4 P61073 1/20 0.40
KDM4E B2RXH2 1/20 0.40
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
ACAT1 P24752 1/20 0.40
SOAT1 P35610 1/20 0.40
CNR1 P21554 2/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
EPHX1 P07099 2/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8632431 0.93 CCR2 (0.46) CCR2CCR1CCR5CXCR4KDM4E
SCHEMBL23812164 0.91 CCR2 (0.48) CCR2CCR1CCR5CXCR4KDM4E
SCHEMBL13036470 0.86 MEN1 (0.47) CCR2CCR1CCR5CXCR4KDM4E
SCHEMBL4431635 0.82 CA1 (0.41) CCR2CCR1CCR5CXCR4KDM4E
SCHEMBL17447494 0.81 CNR1 (0.42) CCR2CCR1CCR5CXCR4KDM4E
SCHEMBL12064065 0.78 ALDH1A1 (0.34) CCR2CCR1CCR5CXCR4KDM4E
SCHEMBL22084111 0.78 EPHX1 (0.34) EPHX1ALDH1A1FDPS
SCHEMBL22828907 0.78 ALDH1A1 (0.38) MEN1KMT2ATDP1EPHX1ALDH1A1
SCHEMBL16925399 0.78 MAPT (0.38) CCR2CCR1CCR5CXCR4KDM4E
SCHEMBL22317358 0.78 CNR1 (0.47) CCR2CCR1CCR5CXCR4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3082877-B1 CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2019-08-28 EP disclosed
US-20170210734-A1 Substituted Azaspiro(4.5)Decane Derivatives GRUENENTHAL GMBH (DE) 2017-07-27 US disclosed
WO-2016008582-A1 SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES Grünenthal GmbH (DE) 2016-01-21 WO disclosed
EP-1951664-A1 ORGANIC SULFUR COMPOUNDS AND USE THEREOF AS ARTHROPODICIDES Sumitomo Chemical Company, Limited (JP) 2008-08-06 EP disclosed
WO-2007060839-A1 ORGANIC SULFUR COMPOUNDS AND USE THEREOF AS ARTHROPODICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170210734-A1 Substituted Azaspiro(4.5)Decane Derivatives OPRL1, OPRM1, OPRD1 CCR2 601/4885CCR1 703/4885CCR5 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.